These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35731976)

  • 1. Drug-Membrane Interactions: Effects of Virus-Specific RNA-Dependent RNA Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers.
    Fischer M; Müller P; Scheidt HA; Luck M
    Biochemistry; 2022 Jul; 61(13):1392-1403. PubMed ID: 35731976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models.
    Wang Y; Li P; Rajpoot S; Saqib U; Yu P; Li Y; Li Y; Ma Z; Baig MS; Pan Q
    Sci Rep; 2021 Dec; 11(1):23465. PubMed ID: 34873274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of remdesivir and favipiravir - the anti-Covid-19 agents mimicking purine RNA constituents.
    Al-Ardhi FM; Novotny L; Alhunayan A; Al-Tannak NF
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):12-20. PubMed ID: 34782799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
    Shahrbaf MA; Tabary M; Khaheshi I
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(2):88-90. PubMed ID: 34387172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
    Zhu W; Chen CZ; Gorshkov K; Xu M; Lo DC; Zheng W
    SLAS Discov; 2020 Dec; 25(10):1141-1151. PubMed ID: 32660307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
    Tsuji M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.
    Negru PA; Radu AF; Vesa CM; Behl T; Abdel-Daim MM; Nechifor AC; Endres L; Stoicescu M; Pasca B; Tit DM; Bungau SG
    Biomed Pharmacother; 2022 Mar; 147():112700. PubMed ID: 35131656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far.
    Saini M; Rana M; Bhatti K; Das R; Mehta DK; Chidurala RM
    Curr Drug Res Rev; 2022; 14(1):11-19. PubMed ID: 34365935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase.
    Celik I; Erol M; Duzgun Z
    Mol Divers; 2022 Feb; 26(1):279-292. PubMed ID: 33765239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA-dependent RNA polymerase: Structure, mechanism, and drug discovery for COVID-19.
    Jiang Y; Yin W; Xu HE
    Biochem Biophys Res Commun; 2021 Jan; 538():47-53. PubMed ID: 32943188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options.
    Sreekanth Reddy O; Lai WF
    Chembiochem; 2021 Mar; 22(6):939-948. PubMed ID: 33031623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the Antivirals Remdesivir and Favipiravir Work Better Jointly? In Silico Insights.
    Parlak C; Alver Ö; Ouma CNM; Rhyman L; Ramasami P
    Drug Res (Stuttg); 2022 Jan; 72(1):34-40. PubMed ID: 34535038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Theaflavin-3'-O-gallate a Black-tea Constituent Blocked SARS CoV-2 RNA dependant RNA Polymerase Active-site with Better Docking Results than Remdesivir.
    Banerjee A; Kanwar M; Maiti S
    Drug Res (Stuttg); 2021 Oct; 71(8):462-472. PubMed ID: 34517419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
    Jung LS; Gund TM; Narayan M
    Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrofluorimetric quantitative analysis of favipiravir, remdesivir and hydroxychloroquine in spiked human plasma.
    Ramzy S; Abdelazim AH; Osman AO; Hasan MA
    Spectrochim Acta A Mol Biomol Spectrosc; 2022 Nov; 281():121625. PubMed ID: 35863184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA Polymerase.
    Naseem-Khan S; Berger MB; Leddin EM; Maghsoud Y; Cisneros GA
    J Chem Inf Model; 2022 May; 62(10):2456-2465. PubMed ID: 35435671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions Between Remdesivir, Ribavirin, Favipiravir, Galidesivir, Hydroxychloroquine and Chloroquine with Fragment Molecular of the COVID-19 Main Protease with Inhibitor N3 Complex (PDB ID:6LU7) Using Molecular Docking.
    Silva Arouche TD; Reis AF; Martins AY; S Costa JF; Carvalho Junior RN; J C Neto AM
    J Nanosci Nanotechnol; 2020 Dec; 20(12):7311-7323. PubMed ID: 32711596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir.
    Yin W; Mao C; Luan X; Shen DD; Shen Q; Su H; Wang X; Zhou F; Zhao W; Gao M; Chang S; Xie YC; Tian G; Jiang HW; Tao SC; Shen J; Jiang Y; Jiang H; Xu Y; Zhang S; Zhang Y; Xu HE
    Science; 2020 Jun; 368(6498):1499-1504. PubMed ID: 32358203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase.
    Wang Q; Wu J; Wang H; Gao Y; Liu Q; Mu A; Ji W; Yan L; Zhu Y; Zhu C; Fang X; Yang X; Huang Y; Gao H; Liu F; Ge J; Sun Q; Yang X; Xu W; Liu Z; Yang H; Lou Z; Jiang B; Guddat LW; Gong P; Rao Z
    Cell; 2020 Jul; 182(2):417-428.e13. PubMed ID: 32526208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.